Purple Biotech Ltd (KTOV)

Etorro trading 970x250
Purple Biotech Ltd (KTOV) Logo

About Purple Biotech Ltd

Purple Biotech Ltd., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various pharmaceutical drugs. It operates through two segments, Oncology, and Pain and Hypertension. The company’s marketed products include Consensi, a fixed-dose combination of celecoxib and amlodipine besylate for the simultaneous treatment of osteoarthritis pain and hypertension in the United States, as well as in China and South Korea. Its oncology pipeline includes NT-219, a small molecule that is advancing as a monotherapy treatment of advanced solid tumors and in combination with cetuximab for the treatment of recurrent or metastatic squamous cell carcinoma of head and neck cancer in a planned phase 1/2 study; and CM-24, a monoclonal antibody blocking CEACAM1 that is being developed as a combination therapy with anti-PD1 checkpoint inhibitors for the treatment of non-small cell lung cancer and pancreatic cancer. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. Purple Biotech Ltd. is headquartered in Tel Aviv, Israel. Address: One Azrieli Center, Tel Aviv, Israel, 6701101

Purple Biotech Ltd News and around…

Latest news about Purple Biotech Ltd (KTOV) common stock and company :

Purple Biotech to Present at the B. Riley Oncology Investor Conference
18 Jan, 2021 FinancialContent
Purple Biotech to Ring the Nasdaq Stock Market Opening Bell
04 Jan, 2021 FinancialContent
Kitov Announces Name Change to Purple Biotech Ltd.
10 Dec, 2020 FinancialContent
Kitov Pharma to Participate in November Investor Conferences
11 Nov, 2020 FinancialContent
Kitov Expands Planned Phase 1/2 Clinical Trial of CM24 in Non-Small Cell Lung Cancer with New Cohort to Evaluate CM24 in Patients with Pancreatic Cancer Conducted with Bristol Myers Squibb
09 Nov, 2020 FinancialContent

The new cohort will explore the combination of CM24, Opdivo (“nivolumab”) and Abraxane (“albumin-bound paclitaxel; nab-paclitaxel”) in patients with pancreatic cancer

Kitov Pharma Receives Notice of Allowance for a U.S. Patent Covering its Anti-Cancer Drug Candidate, NT219
27 Oct, 2020 FinancialContent
38 Stocks Moving in Friday's Pre-Market Session
23 Oct, 2020 FinancialContent

Gainers Socket Mobile, Inc. (NASDAQ: SCKT) rose 65.8% to $2.42 in pre-market trading after the company reported a rise in ...

New Mechanism of Action Data for NT219 Presented at Epigenetics and Metabolism AACR Special Virtual Conference
16 Oct, 2020 FinancialContent

Purple Biotech Ltd (KTOV) is a NASDAQ Common Stock listed in , ,

970x250